DCN Dx has received a growth equity investment from Martis Capital
DCN Dx, a leading provider of contract development services, has received a growth equity investment from Martis Capital.
DCN Dx offers contract development services for clients seeking to explore, develop and commercialize rapid diagnostic tests related to lateral flow assay. DCN Dx supports an array of customers including global diagnostics manufacturers, nonprofits seeking tests for low-resource settings and start-ups launching diagnostic-based products. Over the past 15 years, DCN Dx has successfully developed more than 100 rapid diagnostic tests for its customers.
Martis Capital is a private equity firm which manages more than US$1.2 billion of equity and is focused exclusively on investing in middle-market growth companies in the healthcare industry.
One of Oaklins’ teams in the USA, together with Pegasus Capital, served as a financial advisor to DCN Dx, in connection with a growth equity investment from Martis Capital.


Talk to the deal team

Bradford A. Adams
Managing Director
Boston, United StatesOaklins TM Capital

Michael S. Goldman
Managing Director
New York, United StatesOaklins TM Capital

James McLaren
Managing Director
New York, United StatesOaklins TM Capital
Related deals
SulAmérica and Rede D’Or São Luiz have announced a combination
SulAmérica (B3:SULA11), a leading insurance company in Brazil, has announced a combination with Rede D’Or São Luiz S.A. (B3:RDOR3), the largest Brazilian hospital network. The companies had a combined market value of approximately US$21 billion on 18 February 2022.
Learn moreCyberimpact has been acquired by Oliva Partners
The founders of Cyberimpact have sold the company to Oliva Partners.
Learn moreMatera has acquired a majority stake in Onidata Tecnologia
Matera has acquired a majority stake in Onidata Tecnologia.
Learn more